Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attentuated (TC 83) VEE virus vaccine

D. S. Burke, H. H. Ramsburg, R. Edelman

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

The authors studied the persistence of antibody to Venezuelan equine encephalomyelitis (VEE) virus subtypes in sera of 20 volunteers inoculated seven or nine years previously with attenuated TC-83 VEE virus vaccine. Serological patterns were compared with those of 10 other persons from whom samples of serum were obtained 28 days after vaccination with TC-83 virus. Vaccinees had no other known exposure to a group A arbovirus. Titers of neutralizing antibody of ≥1:10 were measured against the homologous TC-83 strain of virus in all long- and short-term vaccinees. In both groups of vaccinees the percentage of antibody-positive persons and their geometric mean titers of antibody to the epizootic subtypes I-A, I-B, and I-C were higher than titers to the enzootic subtypes I-D, I-E, II, III, and IV. However, proportionally fewer long-term vaccinees than short-term vaccinees had detectable neutralizing antibody reactive with enzootic strains. These results reveal long-lasting circulation of neutralizing antibody to TC-83 virus and closely related epizootic variants in 95%-100% of vaccinees. The relatively lower rate of antibody conversion and the loss of antibody to more antigenically remote enzootic subtypes of VEE virus suggest that vaccinees may be less well protected against infection by these strains.

Original languageEnglish (US)
Pages (from-to)354-359
Number of pages6
JournalJournal of Infectious Diseases
Volume136
Issue number3
DOIs
StatePublished - Jan 1 1977

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attentuated (TC 83) VEE virus vaccine'. Together they form a unique fingerprint.

Cite this